Research programme: infectious diseases therapeutics - Abivax

Drug Profile

Research programme: infectious diseases therapeutics - Abivax

Alternative Names: ABX 202; ABX 221; ABX 309; ABX 311; ABX 544

Latest Information Update: 09 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abivax
  • Class Antivirals; Polyclonal antibodies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Chikungunya virus infections; Dengue; Ebola virus infections

Most Recent Events

  • 09 Sep 2016 Early research in Dengue in France (unspecified route)
  • 09 Sep 2016 Early research in Ebola virus infections, Chikungunya virus infections in France (Parenteral) (Abivax pipeline, September 2016)
  • 09 Sep 2016 Abivax plans phase I trials in Chikungunya virus infections, Dengue, and Ebola virus infections in the year 2017 (Abivax pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top